| Literature DB >> 33717367 |
Romil Singh1, Likhita Shaik2, Ishita Mehra3,4, Rahul Kashyap5, Salim Surani6.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease (COVID-19) pandemic, which has led scientists all over the world to push for the identification of novel therapies for COVID-19. The lack of a vaccine and specific treatment has led to a surge of novel therapies and their publicity in recent times. Under these unprecedented circumstances, a myriad of drugs used for other diseases is being evaluated and repositioned to treat COVID-19 (example- Remdesivir, Baricitinib). While multiple trials for potential drugs and vaccines are ongoing, and there are many unproven remedies with little or no supporting evidence. Presently, discussions are revolving around the use of multivitamins (Vitamin, C, D, A), minerals (selenium, zinc), probiotics, flavonoids, polyphenols, and herbal remedies (curcumin, artemisinin, herbal drinks). Our review delves further into the details of some of these controversial therapies for COVID-19.Entities:
Keywords: Antioxidant; COVID-19; Controversial therapy; Novel therapy; Pneumonia; Review
Year: 2020 PMID: 33717367 PMCID: PMC7931150 DOI: 10.2174/1874306402014010079
Source DB: PubMed Journal: Open Respir Med J ISSN: 1874-3064
Summary of the evidence outlining the effects of Vitamin C use in COVID-19.
|
|
|
|
|---|---|---|
| Fowler III | Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients with Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial | Administration of approximately 15g/day of IV VC for 4 days may reduce the mortality rates in sepsis-related ARDS patients. |
| Carr | A new clinical trial to test high-dose vitamin C in patients with COVID-19 | A new randomized control trial (RCT) tests the effects of IV VC in viral infections in 140 patients. The study will investigate the effects of IV VC with a dose of 24g/day for 7 days vs. placebo. It will assess the requirements for mechanical ventilation and vasopressor drugs, organ failure scores, ICU length of stay, and 28-day mortality. |
| Hemilä | Vitamin C and SARS coronavirus | Three RCTs reported that VC supplementation lowered the incidence of Pneumonia in VC supplemented group, showing that VC may affect the susceptibility of lower respiratory tract infections under specific conditions. |
| Wang | Effects of different ascorbic acid doses on the mortality of critically ill patients: a meta-analysis | IV Ascorbic acid at doses 3-5 g/day decreases the duration of vasopressor support and mechanical ventilation, thus reducing the overall mortality rates in ARDS patients. |
| Messina | Functional Role of Dietary Intervention to Improve | Dietary supplementation with VC, Flavonoids, and polyphenols reduces inflammation and immune response, blocking nuclear NF- B translocation, hence has a potential effect in improving the response in COVID patients. |
| Cheng | Can early and high intravenous doses of vitamin C prevent and treat coronavirus disease 2019 (COVID-19) | COVID-19 patients have high levels of inflammatory markers due to oxidative stress, leading to the activation of important pathways like Nrf 2 signaling. This could lead to modulation in the antioxidant response element (ARE) driven cytoprotective protein expression by various transcription factors. The use of high dose Intravenous VC can be a potential target to prevent and relieve oxidative stress in COVID-19 patients. |
| Shanghai Expert Panel | High Dose Vitamin C Infusions Being Used To Treat COVID-19 | High-dose intravenous. 10g-20g intravenous dosage of VC was used for 8-10 hrs. for 50 moderate and 19 severe COVID-19 cases in China, which led to a successful treatment. Though critical cases needed higher doses, their oxygenation index improved, directing the situation towards cure and discharge. |
| Hemilä | Vitamin C Can Shorten the Length of Stay in the ICU: A Meta-Analysis | High-dose intravenous VC infusions ( |
| Berger | Vitamin C supplementation in the critically ill patient. | Patients under critical care like sepsis, burns, trauma, etc. have an improved clinical outcome when high dose VC (3g/day) is administered for several days. |
| Marik | 1. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective | Severe cases of ARDS show clinical benefit evidenced by improving symptoms and radiological signs with VC supplementation 24-48 hours post ECMO procedures. |
| Fowler III | 1. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in | Critical cases after organ failure have decreased mortality by 16.5%, respiratory assistance requirements by 2.5 days, ICU stays by 3.2 days, and hospital admission by 6.7 days after VC administration. However, inflammatory markers failed to improve significantly during the CITRIS-ALI trial. |
Summary of the evidence outlining the potential role of Vitamin D in COVID-19.
|
|
|
|
|---|---|---|
| Wimalawansa, S.J. | The global epidemic of coronavirus--COVID-19: What we can do to minimize risks 5000 IU/d. | Individuals prone to COVID-19 need to have their VD levels more than 40-60ng/ml by supplementing 10,000IU/day for a few weeks followed by tapering to 5000IU/day. |
| Nair | Vitamin D: The “sunshine” vitamin | Supportive data for the effective role of VD in decreasing the risk of COVID-19 could be highlighted by increased |
| Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention [ | The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in China | Since VD levels decrease with age, it may be important to assess the risk of VD as a factor owing to its high case fatality in older age groups. |
| Grant | Evidence that Vitamin D Supplementation Could | Treatment of Community Acquired Pneumonia (CAP) with VD did not significantly result in complete resolution but led to decreased concentration of IL-6, CRP in diabetic patients. VD contributes to the increased risk of ARDS development. |
| Moraes | 1. Vitamin D deficiency is independently associated with mortality among critically ill patients. | There may be an etiological association between low VD levels, positive blood cultures, and mortality in critically ill patients admitted to ICU. |
Summary of the evidence for the use of Flavonoids and Polyphenols in COVID-19.
|
|
|
|
|---|---|---|
| Deep | Bench/Lab study | They reported in conclusion that flavonoids: Hesperidine, Naringin, and Epigallocatechin Gallate |
| Adem | Bench/ Lab Study | After Molecular docking, the study found that flavonoids like hesperidin and rutin may bind the main protease (Mpro) of COVID-19 better than Nelfinavir. |
| Bhatia | Bench/ Lab Study | They performed Virtual Screening by Molecular Docking approach, which established the top 6 docked polyphenols, which are primarily derivatives of Sanguiin, Theaflavin, Kaempferol, Punicalagin, and Protocatechuic acid. Sanguiin and Theaflavin were proposed to resolve breathing difficulties in patients with extreme COVID-19, as they already are established bronchodilators. |
| Ang | Systematic review | The team reviewed 12 pattern identifications, herbal compositions, and analyzed their herbal formulae, recommended by Chinese guidelines for the treatment of various pediatric COVID-19 stages. After thorough analysis, the herb Armeniacae semen was found to be most frequently used for the treatment of pediatric COVID-19 in the Chinese population. It reduced hyper-responsiveness in the airways and inhibited Th2 cells. |